



POSTER

# Effect of Edirex-Sanovel (pioglitazone) medication on the incidence of dementia

Vera Kapetivadze<sup>1</sup>, R. Tabukashvili<sup>1</sup>, N. Gegeshidze<sup>1</sup>, Kh. Tchaava<sup>1</sup>, T. Lazashvili<sup>1</sup>, Z. Magapheridze<sup>1</sup>, and Z. Grigorashvili<sup>1</sup>

Special Issue on Controversies in Neurology. From the 10<sup>th</sup> World Congress on Controversies in Neurology (CONy), Lisbon, Portugal. 17–20 March 2016.

## Abstract

**Objective:** Peroxisome proliferator activated receptor  $\gamma$ -activating drugs show various salutary effects in preclinical models of neurodegenerative disease. The decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-oriented data sources.

**Methods:** Using observational data from 2012–2015, we analyzed the association of Edirex-Sanovel (pioglitazone) and incidence of dementia in a prospective cohort study of 45 subjects aged  $\geq 60$  years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus. We distinguished between nondiabetics, diabetics without Edirex-Sanovel, diabetics with prescriptions of 6 calendar quarters of Edirex-Sanovel, and diabetics with  $\geq 6$  quarters. Cox proportional hazard models explored the relative risk (RR) of dementia incidence dependent on edirex-sanovel use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidities.

**Results:** Long-term use of pioglitazone was associated with a lower dementia incidence. Relative to nondiabetics, the cumulative long-term use of Edirex-Sanovel reduced the dementia risk by 49% (RR = 0.50,  $p = 0.027$ ). If diabetes patients used Edirex-Sanovel 6 quarters, the dementia risk was comparable to those of nondiabetics (RR = 1.20,  $p = 0.36$ ), and diabetes patients without a Edirex-Sanovel treatment had a 25% increase in dementia risk (RR = 1.27,  $p 0.001$ ). We did not find evidence for age effects, nor for selection into Edirex-Sanovel treatment due to obesity.

**Interpretation:** These findings indicate that Edirex-Sanovel treatment is associated with a reduced dementia risk in initially non-insulin-dependent diabetes mellitus patients. Prospective clinical trials are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.

<sup>1</sup>Department of Internal Medicine, Tbilisi State Medical University, Georgia  
Correspondence: verakap@rambler.ru

Citation: Kapetivadze et al. Effect of Edirex-Sanovel (pioglitazone) medication on the incidence of dementia. International Journal of Clinical Neurosciences and Mental Health 2016; 3(Suppl. 1):P48

Published: 16 March 2016

